Catalyst Pharmaceuticals (CPRX) Misses Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 16, 2020 5:27 PM EDT-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million
-GAAP Net Income of $32 Million for Fiscal Year 2019
-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020
-Firdapse Supply Chain in Solid Position-Significant Safety Stock
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
March 16, 2020 5:26 PM EDT-Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million
-GAAP Net Income of $32 Million for Fiscal Year 2019
-Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020
-Firdapse Supply Chain in Solid Position-Significant Safety Stock
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., March 16, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:... More
